Skip to content 
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. more
| Time Frame | KZIA | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 21.79% | 1.07% | 0.74% |
| 1-Month Return | -11.08% | 1.46% | 1.28% |
| 3-Month Return | -19.12% | 3.51% | 3.6% |
| 6-Month Return | -14.25% | 15.29% | 7.31% |
| 1-Year Return | 40.67% | 7.7% | 11.97% |
| 3-Year Return | -85.44% | 21.02% | 72.07% |
| 5-Year Return | -98.93% | 37.81% | 76.01% |
| 10-Year Return | -98.43% | 139.15% | 258.47% |
| Jun '21 | Jun '22 | Jun '23 | Jun '24 | Jun '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 15.18M | 10.00K | 555.00 | 2.31M | 42.00K | [{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":0.07,"profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":15.2,"profit":true},{"date":"2025-06-30","value":0.28,"profit":true}] |
| Cost of Revenue | - | - | - | - | - | [{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}] |
| Gross Profit | 15.18M | 10.00K | 555.00 | 2.31M | 42.00K | [{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":0.07,"profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":15.2,"profit":true},{"date":"2025-06-30","value":0.28,"profit":true}] |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | [{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":100,"profit":true},{"date":"2025-06-30","value":100,"profit":true}] |
| Operating Expenses | 21.56M | 25.41M | 24.12M | 30.77M | 14.26M | [{"date":"2021-06-30","value":70.06,"profit":true},{"date":"2022-06-30","value":82.58,"profit":true},{"date":"2023-06-30","value":78.4,"profit":true},{"date":"2024-06-30","value":100,"profit":true},{"date":"2025-06-30","value":46.34,"profit":true}] |
| Operating Income | (6.38M) | (25.40M) | (24.12M) | (28.46M) | (14.22M) | [{"date":"2021-06-30","value":-637600000,"profit":false},{"date":"2022-06-30","value":-2539900000,"profit":false},{"date":"2023-06-30","value":-2412396900,"profit":false},{"date":"2024-06-30","value":-2846200000,"profit":false},{"date":"2025-06-30","value":-1421700000,"profit":false}] |
| Total Non-Operating Income/Expense | (2.49M) | 19.09K | 3.43M | 1.43M | (8.16M) | [{"date":"2021-06-30","value":-72.42,"profit":false},{"date":"2022-06-30","value":0.56,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":41.51,"profit":true},{"date":"2025-06-30","value":-237.69,"profit":false}] |
| Pre-Tax Income | (8.90M) | (25.38M) | (20.74M) | (27.05M) | (22.45M) | [{"date":"2021-06-30","value":-890400000,"profit":false},{"date":"2022-06-30","value":-2538200000,"profit":false},{"date":"2023-06-30","value":-2073627200,"profit":false},{"date":"2024-06-30","value":-2704900000,"profit":false},{"date":"2025-06-30","value":-2244800000,"profit":false}] |
| Income Taxes | (484.00K) | (368.00K) | (271.09K) | (271.00K) | (1.75M) | [{"date":"2021-06-30","value":-48400000,"profit":false},{"date":"2022-06-30","value":-36800000,"profit":false},{"date":"2023-06-30","value":-27109200,"profit":false},{"date":"2024-06-30","value":-27100000,"profit":false},{"date":"2025-06-30","value":-174600000,"profit":false}] |
| Income After Taxes | (8.42M) | (25.01M) | (20.47M) | (26.78M) | (20.70M) | [{"date":"2021-06-30","value":-842000000,"profit":false},{"date":"2022-06-30","value":-2501400000,"profit":false},{"date":"2023-06-30","value":-2046518000,"profit":false},{"date":"2024-06-30","value":-2677800000,"profit":false},{"date":"2025-06-30","value":-2070200000,"profit":false}] |
| Income From Continuous Operations | (8.42M) | (24.65M) | (20.47M) | (26.78M) | (20.70M) | [{"date":"2021-06-30","value":-842200000,"profit":false},{"date":"2022-06-30","value":-2464781500,"profit":false},{"date":"2023-06-30","value":-2046518000,"profit":false},{"date":"2024-06-30","value":-2677800000,"profit":false},{"date":"2025-06-30","value":-2070200000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}] |
| Net Income | (8.42M) | (25.01M) | (20.47M) | (26.78M) | (20.70M) | [{"date":"2021-06-30","value":-842000000,"profit":false},{"date":"2022-06-30","value":-2501400000,"profit":false},{"date":"2023-06-30","value":-2046518000,"profit":false},{"date":"2024-06-30","value":-2677800000,"profit":false},{"date":"2025-06-30","value":-2070200000,"profit":false}] |
| EPS (Diluted) | - | - | - | - | - | [{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| KZIA | |
|---|---|
| Cash Ratio | 0.31 |
| Current Ratio | 0.35 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| KZIA | |
|---|---|
| ROA (LTM) | -64.28% |
| ROE (LTM) | -3891.64% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| KZIA | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 2.37 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -1.37 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| KZIA | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 35.89 |
| P/B | 3.09 |
| Price/FCF | NM |
| EV/R | 1814.14 |
| EV/Ebitda | NM |
Kazia Therapeutics Ltd ADR (KZIA) share price today is $6.26
Yes, Indians can buy shares of Kazia Therapeutics Ltd ADR (KZIA) on Vested. To buy
Yes, you can purchase fractional shares of Kazia Therapeutics Ltd ADR (KZIA) via the Vested app. You can start investing in Kazia Therapeutics Ltd ADR (KZIA) with a minimum investment of $1.
You can invest in shares of Kazia Therapeutics Ltd ADR (KZIA) via Vested in three simple steps:
The 52-week high price of Kazia Therapeutics Ltd ADR (KZIA) is $17.4. The 52-week low price of Kazia Therapeutics Ltd ADR (KZIA) is $2.86.
The price-to-earnings (P/E) ratio of Kazia Therapeutics Ltd ADR (KZIA) is
The price-to-book (P/B) ratio of Kazia Therapeutics Ltd ADR (KZIA) is 3.09
The dividend yield of Kazia Therapeutics Ltd ADR (KZIA) is 0.00%
The market capitalization of Kazia Therapeutics Ltd ADR (KZIA) is $65.64M
The stock symbol (or ticker) of Kazia Therapeutics Ltd ADR is KZIA
Consider the share price of Kazia Therapeutics Ltd ADR as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Kazia Therapeutics Ltd ADR has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Kazia Therapeutics Ltd ADR shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Kazia Therapeutics Ltd ADR stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Kazia Therapeutics Ltd ADR and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Kazia Therapeutics Ltd ADR stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
